19 completed, 5 recruiting, 2 unknown, 1 active not recruiting. 4 Not applicable, 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Mucormycosis: new trials by email Literature Review of Mucormycosis trials Research Report on Mucormycosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction. Patient-specific titanium implants for facial reconstruction - Hemifacial Microsomia, Mucormycosis | Not applicable | Recruiting | Latakia University | 30 | 2026-04-26 | 2026-06-17 |
| Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project Mucormycosis - Mucormycosis | Recruiting | M.D. Anderson Cancer Center | 300 | 2025-10-20 | 2026-07-14 | |
| Isavuconazole in Critically Ill Patients: Efficacy and Safety Isavuconazole treatment - Fungal Infection, Aspergillosis | Not yet recruiting | Shanghai 10th People's Hospital | 75 | 2025-08-01 | 2025-07-23 | |
| Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study Amphotericin B, Isavuconazole - Mucormycosis | Active not recruiting | Qiu Ye | 150 | 2025-05-15 | 2025-09-25 | |
| Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole - Mucormycosis in Hematologic Malignancies | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2025-03-25 | 2025-09-22 | |
| Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China Mucormycosis, Hematologic Malignancies | Completed | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2025-02-08 | 2026-03-05 | |
| Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children Theraputic drug monitoring, Isavuconazole - Aspergillosis Invasive, Mucormycosis | Not applicable | Recruiting | Shanghai Children's Medical Center | 200 | 2024-06-06 | 2024-12-13 |
| Rehabilitation With an Obturator in Maxillary Defects Obturator Prosthetic Rehabilitation - Mucormycosis | Completed | Menoufia University | 42 | 2024-06-01 | 2026-08-25 | |
| Biomarkers for Invasive Mucormycosis Venous sample - Mucorales Infection, Mucormycosis | Recruiting | University Hospital, Lille | 100 | 2023-11-29 | 2026-05-22 | |
| Mucorales PCR Screening in At-risk Hematology Patients Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands) - Mucormycosis | Not applicable | Unknown | Universitaire Ziekenhuizen KU Leuven | 80 | 2023-11-06 | 2023-12-05 |
| Amphotericin Versus Posaconazole for Pulmonary Mucormycosis Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B - Mucormycosis; Pulmonary (Etiology) | Phase 2 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 82 | 2022-07-01 | 2026-05-22 |
| COVID-19 and Rhino-orbital Mucormycosis Mucormycosis | Completed | Minia University | 40 | 2021-12-28 | 2023-10-18 | |
| Post Marketing Surveillance (PMS) Study of Cresemba in Korea. Isauvuconazole group - Aspergillosis, Mucormycosis | Completed | Pfizer | 94 | 2021-10-28 | 2026-04-13 | |
| Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran COVID-19, Mucormycosis | Unknown | Isfahan University of Medical Sciences | 250 | 2021-08-23 | 2021-10-28 | |
| Mucormycosis in COVID-19 Covid19, Mucormycosis | Completed | Montefiore Medical Center | 728 | 2021-05-24 | 2023-04-18 | |
| World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt debridment - Mucormycosis; Rhinocerebral (Etiology), COVID-19 | Phase 1 / Phase 2 | Completed | Nasser Institute For Research and Treatment | 35 | 2021-05-23 | 2024-02-20 |
| Post-COVID-19 Mucormycosis in Critical Care Mucormycosis; Rhinocerebral (Etiology), Post COVID-19 Condition, Unspecified | Completed | Zagazig University | 150 | 2021-05-01 | 2023-06-20 | |
| A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions. Isavuconazole - Invasive Aspergillosis, Mucormycosis | Completed | Pfizer | 307 | 2021-03-10 | 2025-12-09 | |
| COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital antiviral, surgical - Mucormycosis | Completed | Assiut University | 433 | 2021-03-01 | 2021-10-12 | |
| Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU Covid-19 | Completed | Rennes University Hospital | 576 | 2020-05-04 | 2021-03-30 |
Showing 20 of 28. Sign in to see all of them.
Aspergillosis (6) · COVID-19 (5) · Mycoses (4) · Invasive Fungal Infections (3) · Candidiasis (2) · Cryptococcosis (2) · Hematologic Neoplasms (2) · Zygomycosis (2) · Eye Infections (1) · Facial Asymmetry (1) · Fibrous Dysplasia of Bone (1) · Goldenhar Syndrome (1) · Leukemia (1) · Neutropenia (1)
Bacterial Infections and Mycoses (28) · Infections (28) · Zygomycosis (26) · Mycoses (24) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Coronaviridae Infections (5) · Coronavirus Infections (5) · Lung Diseases (5) · Nidovirales Infections (5) · Pneumonia (5) · Pneumonia, Viral (5) · RNA Virus Infections (5) · Virus Diseases (5) · Neoplasms (4)
isavuconazole (5) · liposomal amphotericin B (3) · posaconazole (2) · Amphotericin B (1) · Antiviral Agents (1) · Blood Specimen Collection (1) · Deferasirox (1) · Dosage Forms (1) · Surgical Procedures, Operative (1) · Voriconazole (1)
Institute of Hematology & Blood Diseases Hospital, China (2) · Latakia University (2) · Pfizer (2) · Asahi Kasei Therapeutics Corporation (1) · Assiut University (1) · Centre Hospitalier Universitaire de Besancon (1) · Fungal Infection Study Forum (1) · Isfahan University of Medical Sciences (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · M.D. Anderson Cancer Center (1) · Menoufia University (1) · Merck Sharp & Dohme LLC (1) · Minia University (1) · Montefiore Medical Center (1) · Nasser Institute For Research and Treatment (1)
France (6) · Egypt (5) · China (4) · United States (3) · India (2) · Syria (2) · Belgium (1) · Germany (1) · Iran (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Ahmad Ahmad, Master (1) · Ali Khalil, PHD (1) · Ayman Sadek, MD (1) · Basim A Slim (1) · Brad Spellberg, MD (1) · Dimitrios Kontoyiannis, MD (1) · Hekmat Yacoub, PHD (1) · Juan Wu, PhD (1) · Mohammed A. El-Sawy, PhD (1) · Mohsen Pourazizi, M.D. (1) · Romaric Larcher, MD, PharmD, MSc (1) · Sizhou Feng (1)
PMID 16436724, PMID 21937481, PMID 27259708, PMID 31002789, PMID 33494021, PMID 34833346, PMID 34843666, PMID 35191210, PMID 35534499, PMID 35734651, PMID 36307059, PMID 39443403, PMID 40619554, PMID 40655799